TCS Industries Limited (China-sourced API supplier) supplies Remdesivir — API CAS 1809249-37-3 for pharmaceutical B2B procurement — COA, MSDS, and technical documentation available on request.
> Overview
| Product Name | Remdesivir |
|---|---|
| Structural Formula |  |
| CAS Number | 1809249-37-3 |
| Molecular Formula | C₂₇H₃₅N₆O₈P |
| Molecular Weight | 602.6 g/mol |
| InChIKey | RWWYLEGWBNMMLJ-YSOARWBDSA-N |
| SMILES | Available on request where applicable |
| Appearance | White to off-white powder |
| Purity / Grade | By agreed specification and batch COA |
| Storage | Room temperature (lyophilized); 2–8°C (solution concentrate) |
Remdesivir (CAS 1809249-37-3, development code GS-5734) is a nucleotide analog prodrug with the formula C₂₇H₃₅N₆O₈P (MW 602.58). It is metabolized intracellularly to an active adenosine triphosphate analog (GS-443902) that inhibits RNA-dependent RNA polymerase (RdRp). Remdesivir was originally developed for Ebola virus and received emergency use authorization and subsequent approval for COVID-19.
TCS Industries Limited, a Hong Kong-based trading and sourcing company, supplies Remdesivir API in pharmaceutical grade for global procurement programs.
> Applications
Antiviral RNA polymerase inhibition
Remdesivir IV 200 mg day 1, then 100 mg daily for 5 days (up to 10 days) was the first FDA-approved treatment for COVID-19. The active metabolite is incorporated into the viral RNA strand by RdRp, causing delayed chain termination. It has broad-spectrum activity against RNA viruses (coronaviruses, Ebola, Nipah, RSV). Beigel et al. (N Engl J Med, 2020, 383:1813–1826) reported the results of the ACTT-1 trial showing that remdesivir shortened recovery time in hospitalized COVID-19 patients requiring supplemental oxygen.
Pandemic preparedness applications
Remdesivir demonstrated antiviral activity against SARS-CoV, MERS-CoV, and Ebola virus in preclinical studies. Its broad coronavirus activity and established manufacturing platform position it as a pandemic preparedness therapeutic. Three-day courses have been evaluated for early-stage COVID-19 treatment in outpatient settings.
> Sourcing & Supply
TCS Industries Limited supports development, qualification and commercial purchasing discussions for Remdesivir with buyers in Australia, New Zealand, Canada and South Korea.
- Evaluation and commercial quantities: 100 g samples for analytical qualification; 1 kg and 5 kg for production. Pharmaceutical-grade crystalline powder for lyophilized injection formulation. Cold chain may be required. DMF reference letters available.
- Pallet quantities and production campaigns: repeat supply is coordinated against packaging, lead time, annual demand and destination-market import requirements.
> Quality & Documentation
Key specification parameters include assay (≥98.0%), related substances (Nuc-nucleoside ≤1.0%), stereochemical purity (Sp diastereomer ≥99%), water content, residual solvents, heavy metals, endotoxin (for parenteral grade), and microbial limits. White to off-white crystalline powder. Slightly soluble in water. Contains a phosphoramidate prodrug moiety. Identity by HPLC, ³¹P NMR, and IR. Meets in-house pharmaceutical specifications. COA and MSDS are standard.
> Packaging
Remdesivir is a white to off-white crystalline powder. Standard packaging includes sealed glass vials or double-sealed foil bags under nitrogen (100 g, 500 g, or 1 kg). Store at controlled room temperature (15–25 °C) or 2–8 °C per manufacturer specification. Protect from light and moisture. Shelf life is typically 24–36 months. Labels and documents are checked before dispatch.
> Pricing & MOQ
Pricing is quoted by specification, packaging and destination. Common commercial discussions use 25 kg bag/drum formats, pallet quantities and production-campaign planning; smaller samples may be reviewed for qualified formulation teams.
> Regulatory & Compounding Context
Remdesivir received FDA Emergency Use Authorization in May 2020 and full approval in October 2020 (Veklury, Gilead). EMA conditional marketing authorization in 2020. WHO has issued conditional recommendations. Generic remdesivir production licensed to multiple manufacturers under voluntary licensing agreements. DMF and regulatory documentation available.
> Alias Index
- INN: Remdesivir
- CAS Number: 1809249-37-3
- Formula: C₂₇H₃₅N₆O₈P (MW 602.58)
- Development code: GS-5734
- Brand name: Veklury (Gilead Sciences)
- ATC code: J05AB16
- Active metabolite: GS-443902 (adenosine triphosphate analog)
- Commercial request terms: remdesivir API, Veklury generic, GS-5734, RdRp inhibitor, antiviral API, TCS Industries Limited
> FAQ
How does Remdesivir inhibit viral replication?
Remdesivir undergoes intracellular metabolism to GS-443902 (adenosine triphosphate analog). RdRp incorporates this analog into the growing RNA strand. After three additional nucleotides are added, chain elongation terminates (delayed chain termination). This mechanism evades the proofreading exonuclease (ExoN) of coronaviruses that would remove immediately-terminating analogs.
What documents are available for Remdesivir orders?
COA and MSDS are standard for commercial discussions. COO, packing list, invoice and other import-support documents can be arranged according to order scope.
Do you supply Remdesivir to Australia and Canada?
Yes. We support B2B buyers in Australia, New Zealand, Canada and South Korea, subject to route and document review.
Do you supply New Zealand and South Korea?
Yes. We review Australia, New Zealand, Canada and South Korea for project supply, import documents, packaging and logistics planning before quotation.
Why is Remdesivir given IV only?
Remdesivir has low oral bioavailability due to extensive first-pass hepatic metabolism that degrades the phosphoramidate prodrug before it reaches target cells. The IV route delivers the intact prodrug to hepatocytes and other target cells for intracellular activation. Oral prodrug variants are under development to address this limitation.
Is generic Remdesivir available?
Yes. Gilead granted voluntary licenses to generic manufacturers (primarily in India, Egypt, and other developing countries) through the Medicines Patent Pool. These licenses allow production for 127 low- and middle-income countries. Multiple generic manufacturers produce remdesivir under these agreements.
Can you arrange samples before commercial purchasing?
Samples or evaluation quantities may be reviewed for qualified buyers after target specification, application and destination-market requirements are clarified.
How is Remdesivir packaged for export?
Packaging is confirmed by quantity and material properties. Typical options include foil bags, HDPE containers, fibre drums, 25 kg bags or palletized export packaging.
Can buyer-defined specifications be reviewed?
Yes. Send the specification, methods, impurity limits and required documents. TCS can review feasibility before confirming quotation and lead time.
What payment terms are normally used?
Standard payment is 100% T/T before dispatch unless a different arrangement has been approved for an established commercial account.
What lead time should buyers expect?
Lead time depends on stock, batch size, document scope and destination. Available stock can move faster; made-to-order or pallet programs require longer planning.
Is a DMF available?
Yes. TCS sources remdesivir from manufacturers who maintain active regulatory filings. Generic production is established under voluntary licensing. COA, stability data, and regulatory documentation are provided. Buyers should confirm licensing terms for their target market.
Last reviewed: June 2026
Evaluation and research orders (≤10 kg) are shipped with COA, MSDS, and certificate of origin. Bulk commercial orders (>10 kg) qualify for volume pricing with a full technical documentation package available on request.
> Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.